TEGAFUR 20 mg + GIMERACIL 5.8 mg + OTERACIL 15.8 mg (Tegonat) × 42 Capsules

Uses of Tegonat

• Treatment of advanced stomach cancer
• May be combined with other chemotherapy medicines
• Treatment of metastatic colorectal cancer in selected patients, where approved
• Other uses may be considered only by an oncologist

Benefits of Tegonat

• Slows cancer-cell growth
• Helps control cancer progression
• Provides an oral chemotherapy option
• Can be used with other cancer treatments

How Does Tegonat Work?

Tegafur is converted into fluorouracil (5-FU) inside the body, which interferes with cancer-cell DNA production and slows or stops cancer growth. Gimeracil helps maintain fluorouracil levels by slowing its breakdown, while oteracil helps reduce its effects on healthy tissues in the digestive system.

Possible Side Effects

• Nausea or vomiting
• Diarrhoea
• Loss of appetite
• Tiredness or weakness
• Mouth sores
• Reduced blood-cell counts
• Increased risk of infection
• Anaemia

Precautions

• Use only with a valid prescription and oncology supervision.
• DPD deficiency testing may be required before treatment.
• Inform your doctor about kidney, liver or blood-related problems.
• Regular blood, kidney and liver function tests may be required.
• Tell your doctor about every medicine and supplement you use.
• Avoid use during pregnancy and breastfeeding.
• Use effective contraception as advised by your doctor.
• Seek medical help for severe diarrhoea, fever, bleeding, chest pain or persistent vomiting.

Tegafur, Gimeracil and Oteracil Price and Reimbursement Information by Country

Tegafur, Gimeracil and Oteracil prices may vary between countries depending on the brand, strength, pack size, pharmacy, insurance coverage, government subsidies, taxes and local healthcare policies. The following resources provide country-specific pricing, reimbursement, regulatory or medicine information.

• View medicine information on NICE BNF (UK) – https://bnf.nice.org.uk/drugs/tegafur-with-gimeracil-and-oteracil-specialist-drug/
• View the Teysuno medicine recommendation from NHS Wales – https://awttc.nhs.wales/accessing-medicines/medicine-recommendations/tegafur-gimeracil-oteracil-teysuno/
• View Teysuno regulatory information from the European Medicines Agency – https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno
• View published clinical and regulatory background information on PubMed Central – https://pmc.ncbi.nlm.nih.gov/articles/PMC3233278/